SCHEMBL1747309

SCHEMBL1747309

O=C(O)CCc1ccc(OCc2ccc(NC(=O)c3ccccc3)cc2)cc1

nearest known ligand 0.78

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.78
NPC1 O15118 3/20 0.78
SMN1; SMN2 Q16637 1/20 0.78
FFAR1 O14842 9/20 0.70
FFAR4 Q5NUL3 3/20 0.70
KMT2A Q03164 6/20 0.69
MEN1 O00255 5/20 0.69
RXFP1 Q9HBX9 2/20 0.69
LMNA P02545 1/20 0.65
POLB P06746 2/20 0.62
TDP1 Q9NUW8 2/20 0.62
NR1H4 Q96RI1 2/20 0.59
KDM4E B2RXH2 1/20 0.57
DUSP3 P51452 1/20 0.57
PTPN5 P54829 1/20 0.57
PTPN11 Q06124 1/20 0.57
CTDSP1 Q9GZU7 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1746787 0.89 RAB9A (0.72) RAB9ANPC1SMN1; SMN2FFAR1FFAR4
SCHEMBL4964241 0.88 NPC1 (1.00) RAB9ANPC1SMN1; SMN2KMT2AMEN1
SCHEMBL1232960 0.88 NR1H4 (0.71) RAB9ANPC1FFAR1FFAR4KMT2A
SCHEMBL22192264 0.85 RAB9A (0.94) RAB9ANPC1SMN1; SMN2KMT2AMEN1
SCHEMBL1747121 0.84 HDAC1 (0.79) RAB9ANPC1FFAR1FFAR4KMT2A
SCHEMBL1744939 0.83 FFAR1 (1.00) FFAR1FFAR4POLBTDP1
Benzyloxyphenylpropanoic Acid SCHEMBL1134648 0.83 FFAR1 (1.00) FFAR1FFAR4POLBTDP1
SCHEMBL1744622 0.82 FFAR1 (0.80) RAB9ASMN1; SMN2FFAR1FFAR4
Benzyloxyphenylpropanoic Acid SCHEMBL30117578 0.82 FFAR1 (0.97) FFAR1FFAR4POLBTDP1
SCHEMBL2772440 0.82 FFAR1 (1.00) FFAR1FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR RAB9A 2029/4885NPC1 1470/4885SMN1; SMN2 4589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.